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Abstract
Guidelines recommend adults with pituitary disease in whom GH therapy is contemplated, to be tested for GH 
deficiency (AGHD); however, clinical practice is not uniform.
Aims: (1) To record current practice of AGHD management throughout Europe and benchmark it against guidelines; (2) 
To evaluate educational status of healthcare professionals about AGHD.
Design: Online survey in endocrine centres throughout Europe.
Patients and methods: Endocrinologists voluntarily completed an electronic questionnaire regarding AGHD patients 
diagnosed or treated in 2017–2018.
Results: Twenty-eight centres from 17 European countries participated, including 2139 AGHD patients, 28% of 
childhood-onset GHD. Aetiology was most frequently non-functioning pituitary adenoma (26%), craniopharyngioma 
(13%) and genetic/congenital midline malformations (13%). Diagnosis of GHD was confirmed by a stimulation test 
in 52% (GHRH+arginine: 45%; insulin-tolerance: 42%, glucagon: 6%; GHRH alone and clonidine tests: 7%); in the 
remaining, ≥3 pituitary deficiencies and low serum IGF-I were diagnostic. Initial GH dose was lower in older  
patients, but only women <26 years were prescribed a higher dose than men; dose titration was based on normal 
serum IGF-I, tolerance and side-effects. In one country, AGHD treatment was not approved. Full public reimbursement  
was not available in four countries and only in childhood-onset GHD in another. AGHD awareness was low among  
non-endocrine professionals and healthcare administrators. Postgraduate AGHD curriculum training deserves  
being improved.
Conclusion: Despite guideline recommendations, GH replacement in AGHD is still not available or reimbursed in all 
European countries. Knowledge among professionals and health administrators needs improvement to optimise the 
care of adults with GHD.
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Adult growth hormone deficiency (AGHD) affects between 
200 and 300 patients/million population, approximately 
100 000 patients across Europe (1). The condition is 
characterised by a reduction in bone mineral density, lean 
body mass, exercise capacity, and overall health-related 
quality of life as well as an increase of body fat and an 
adverse cardiovascular risk profile (2, 3). The concept of 
AGHD was established more than 30 years ago, and the 
accumulated evidence is nowadays overwhelming that 
most patients benefit from a daily injection of GH and are 
willing to continue treatment (4, 5, 6, 7, 8, 9, 10, 11, 12, 
13, 14). Nevertheless, a small percentage of patients do 
not perceive any benefit and prefer not to be GH replaced 
(15, 16).
Current guidelines recommend that patients with 
pituitary disease should be tested and treated for AGHD 
(17, 18, 19, 20). Still, it is not universally recognised as 
a distinct entity and reimbursement for GH replacement 
therapy is not available in some countries. The European 
Society of Endocrinology (ESE) therefore aimed to 
investigate the current practice of AGHD management 
to benchmark it against existent guidelines (17, 18, 
19, 20). The goal was to collect aggregated patient data 
from regional centres representing several thousand 
individuals, with either treated or untreated AGHD.
Patients and methods
An ESE Steering Group prepared an online survey to 
collect information on diagnosis and treatment practices 
country by country (https://www.ese-hormones.org/
aghd) and to compare everyday practice with guideline 
recommendations.
Invitations to participate were distributed at ECE2018, 
through the Rare Endocrine Disease European Reference 
Network (Endo-ERN) and the ESE Council of Affiliated 
Societies (ECAS). Suitable centres were those from Europe, 
who currently treated at least 10 AGHD patients per year 
or who could not treat AGHD due to local conditions and 
restrictions. We identified 70 centres which were invited 
to participate repeatedly, via e-mail. Finally, 28 centres 
from 17 European countries were included.
The survey consisted of 44 questions (Supplementary 
Table, see section on supplementary materials given at the 
end of this article) and included sections on demographics, 
diagnostic criteria, patient selection, GH dosing and 
follow up, safety and treatment goals. Patients diagnosed 
and/or treated between 01/01/2017 and 31/12/2018 were 
included. Additionally, ten questions reflected the practice 
and perspectives of each centre as reported by the senior 
endocrinologist in charge, namely sections on national 
statistics on AGHD, country treatment reimbursement 
policies and distribution of the drug, available education 
and training resources and the level of satisfaction related 
to AGHD in each local setting. Questions were developed 
on the basis of published guidelines (17).
Individual patient data were captured in a dedicated 
Access database (Form A). An aggregated data summary 
form was generated (Form B), which was the basis of the 
information submitted to the ESE in an online e-survey 
(Form C and Supplementary Table), which also captured 
the questions on local practices and current site-specific 
perspectives.
Since the survey did not include personal medical 
questions but a summary of patient data and clinical 
practise per centre, ethics approval was not required in all 
countries, however, when necessary, participants obtained 
local approval by their ethics committee.
Statistical analysis
Descriptive statistics and Student’s t-test, Chi-squared 
or ANOVA tests were used to analyse the data, where 
appropriate. A level of P <0.05 was considered significant. 
Analyses were performed using SPSS21.0 (SPSS Inc., 
Chicago, IL).
Results
In January 2020, 28 Form C-s (online survey) were 
collected from 28 centres in 17 countries. The largest 
contributing countries were Italy (five centres) and Spain 
(four centres). The general characteristics of participating 
centres and patients are summarised in Fig. 1.
Based on the published prevalence of AGHD in 
different countries (1), the estimated and captured AGHD 
patients per country are shown in Table 1; Denmark (32%) 
and Slovenia (20%) were the countries with the highest 
participation.
In order to evaluate the global experience of each 
centre in the management of pituitary patients, the 
total number of pituitary patients, as well as surgical 
and radiotherapy treatments per year were collected, 
independently of their GHD status (Fig. 2). Nine centres 
declared to follow more than 500 pituitary patients 
per year (Barcelona, Genoa, Ljubljana, Lyon Marseille, 
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Number and general characteristics of countries, centres and patients involved in the study. aCountries: Bulgaria, Croatia, 
Denmark, France, Greece, Hungary, Italy, Lithuania, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, 
United Kingdom. *GH treatment ongoing at survey initiation (January 1, 2017). **Prior GH therapy received, but interrupted at 
survey initiation (January 1, 2017). CO-AGHD, childhood-onset adult growth hormone deficiency; AO-AGHD, adult-onset adult 
growth hormone deficiency.









Percentage of captured AGHD patients 
based on estimated number of patients (%)
Bulgaria 7 1225 87 7
Croatia 4 700 25 4
Denmark 5 875 281 32
France 66 11 550 206 1
Greece 10 1750 28 2
Hungary 10 1750 45 3
Italy 60 10 500 622 6
Lithuania 3 525 10 2
Portugal 10 1750 65 4
Romania 19 3325 83 2
Serbia 7 1225 30 2
Slovakia 5 875 67 8
Slovenia 2 350 70 20
Spain 46 8050 192 3
Sweden 10 1750 254 14
Switzerland 9 1575 18 1
UK 66 11 550 91 1
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Number of pituitary patients and identified AGHD patients followed and pituitary surgeries and pituitary radiotherapies 
performed on average per year in each centre. (A) Centres that follow ≥500 pituitary patients; (B) centres that follow <500 to >100 
pituitary patients; (C) centres that follow ≤100 patients. AGHD, adult growth hormone deficiency.
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Messina, Sheffield, Stockholm and Turin), another 
10, between 100 and 500 patients (Aarhus, Athens, 
Basel, Bratislava, Bucharest, Milan, Sophia, Tenerife, 
Thessaloniki, Zagreb) and the remaining, 100 patients or 
less per year (between 20 and 100).
The aetiology of AGHD and the degree of 
hypopituitarism are shown in Table 2. The most common 
cause of AGHD was a non-functioning pituitary adenoma 
(26% of all cases reported), followed by craniopharyngioma 
and genetic or congenital midline malformations (13% 
each). Only 4% had isolated GHD; 22% had diabetes 
insipidus and most patients had additional pituitary 
hormone deficiencies.
Twenty-eight per cent (n = 594) corresponded to 
patients with childhood-onset AGHD (CO-AGHD); 
among those with adult-onset AGHD (AO-AGHD), age 
of diagnosis was from 18 to 25 years in 10%; between 26 
and 45 years in 29%; 46–65 years in 28%; and older than 
65 years, less than 5%. Distribution of age at GH treatment 
initiation was similar (<18 years-old: 22%; 18–25 years-old: 
13%; 26–45 years old: 31%; 46–65 years old: 30%; >65 years 
old: 4%), indicating that, in general, there was no delay in 
treatment initiation after the diagnosis of GHD.
As far as the tests used to diagnose AGHD, 1103 
patients (52%) underwent a stimulation test, mainly a 
GHRH+arginine test (45%) or an insulin tolerance test 
(ITT) (42%); in 6% a glucagon test was performed and 
other tests in another 7% including GHRH alone and 
clonidine. Fourteen per cent (n = 305) of patients did 
not undergo any GH stimulation test but were diagnosed 
on the basis of 3 or more other pituitary deficiencies 
plus a low serum IGF-I (reported in 54% of the centres 
to be enough to diagnose AGHD). In the remaining 34% 
(n = 731) of patients, information on stimulation tests was 
unavailable. Figure 3 depicts the diagnostic test preference 
in specific clinical situations when a test was either 
clinically contraindicated or was of limited diagnostic 
accuracy.
When all other endocrine axes are normal, 34% 
of centres do not perform a stimulation test even if an 
underlying pituitary disease exists, since it is not an 
indication for substitution therapy in many countries.
The diagnostic cut-off for the ITT test used to diagnose 
GH deficiency was <3 µg/L, except for three centres which 
used the cut-off <5 µg/L (Bratislava, Madrid and Sheffield). 
The diagnostic cut-off for the GHRH+arginine test was <9 
µg/L in Italy in patients with a BMI <30 kg/m2 and <4 
μg/L in patients with a BMI ≥30 kg/m2 and <6 µg/L in 
Denmark, irrespective of BMI, while in other countries 
(Romania, Sweden, Switzerland and United Kingdom) a 
peak of <11, <8 or <4 was considered diagnostic of AGHD 
when BMI is <25, 25–30, or >30 kg/m2, respectively. Two-
thirds of the centres (18/28) required IGF-I to be low to 
initiate GH therapy, while this was not necessary for the 
remaining 10 centres.
When considering GH substitution therapy, patient 
compliance and symptoms (i.e. impaired quality of life 
and severe fatigability) were important determinants 
for initiating treatment (Table 3); age under 65 years 
and central obesity, however, were only considered by 
11% of participating centres. Administrative issues (i.e. 
lack of reimbursement and restrictions to provide the 
drug in hospital pharmacies) were the main reason why 
GH therapy was not initiated in countries like Romania 
(100% of untreated patients), Portugal and Greece (90%), 
Lithuania (70%) and Bulgaria (60%). After diagnosis of 
AGHD and no coexistent contraindications, treatment 
was begun in some but not all centres (Fig. 4). As far as the 
Table 2 Aetiology of adult growth hormone deficiency (AGHD) 
and the degree of hypopituitarism in the patient cohort.









 Other pituitary mass 




 Cranial irradiation due 
to another malignant 
disease
117 6





 Idiopathic isolated GHD 81 4
 Traumatic brain injury 57 3
 Treated acromegaly 50 2
 Other 143 7
 Not known 82 4
Other pituitary deficiencies*
 No other pituitary 
deficiency
162 8
 TSH deficiency 1754 82
 LH/FSH deficiency 1622 76
 ACTH deficiency 1491 70
 ADH deficiency 467 22
 PRL deficiency 150 7
*Centres were allowed to choose more than one deficiency per patient.
ACTH, adrenocorticotrophin hormone; ADH, antidiuretic hormone; FSH, 
follicle-stimulating hormone; GHD, growth hormone deficiency; LH, 
luteinising hormone; PRL, prolactin; TSH, thyroid stimulation hormone.
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starting dose of GH, 0.3 mg/day was most often prescribed 
as first choice in those aged 26–45 years, and 0.2 mg/day 
in those aged 46 to above 65 years, irrespective of gender. 
However, in patients aged 25 years or younger, higher 
doses were prescribed in women (0.75 mg/day if <18 years 
and 0.5 mg/day if aged between 18 and 25) than in men 
(0.2 mg/day). In Portugal, the initial dose was prescribed 
according to the patient’s body weight.
Most recommended administering GH injections in 
the evening (60%) and considered a switch from oral to 
transdermal or transvaginal oestrogens (10%), increased 
monitoring for patients >65 years old (4%), checking 
of free T4 when taking thyroxin replacement therapy 
(57%) and considering an increase in hydrocortisone 
replacement dose (26%).
In 284 patients, GH substitution had been interrupted 
at the time of the survey. The causes of GH treatment 
interruption are shown in Table 4. Adverse events were 
responsible in 57% of the cases, while lack of compliance, 
administrative reasons and lack of perceived improvement 
while on therapy, and death (4%) were also reported.
As far as the transitioning from childhood to adult 
care, the age was >18 years in 19 centres and between 14 
and 18 years in another 8 centres (this information was 
missing in the remaining centre). Most of the CO-AGHD 
patients were referred by the paediatrician or another 
practitioner to adult care (68%), although 17% were 
seen after direct patient inquiry. In the remaining (15%), 
this information was unavailable. In 224/594 CO-AGHD 
patients, GH substitution was interrupted during 
transitioning to adult care for more than 24 months 
(n = 157). The reasons for GH treatment interruption 
during transition to adult care are shown in Table 5. 
While lack of reimbursement and patients own decision 
to stop GH treatment was the most frequent reason 
for treatment interruption, discharge by the paediatric 
Figure 3
Number of centres that chose to perform different stimulation tests in specific situations. Centres were allowed to choose more 
than one test per each situation. ITT, Insulin tolerance test; GHRH, growth hormone-releasing hormone.
Table 3 Features considered when initiating growth 
hormone (GH) substitution therapy. Data is presented as n (%).
 Centres  
(n = 28)
Patients  
(n = 2139) 
Requirements for GH  
treatment initiation*
 Patient compliance 21 (75)
 Impaired quality of life 12 (43)
 Severe fatigability  9 (32)
 Age <65 years  3 (11)
 Central obesity  3 (11)
 Others** 2 (7)
Factors that stopped initiation  
of GH therapy*** 
 Administrative issues  220 (10)
 Compliance considerations 119 (6)
 Persistent and stable pituitary 
tumour rests
 96 (4)
 Age >65 years  52 (2)
 Concomitant diabetes mellitus  20 (1)
 Other 141 (7)
 None 1270 (59)
*Centres were allowed to choose more than one requirement; **No 
current or prior history of malignancy (Athens) and decreased bone 
mineral density (Madrid); ***Centres were allowed to choose more than 
one factor per patient.
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consultant or poor patient compliance and difficulty in 
referral to an adult clinic were also reported.
As far as follow-up after starting GH therapy, half 
the centres measured IGF-I 2–3 months after initiating 
treatment and every 12 months once a stable dose was 
reached. Considering the targeted IGF-I concentration 
to be reached during treatment, 40% aimed at a value 
within the normal range, 26% within the mid-normal 
range, 14% aimed at a high-normal range, and 3% aimed 
at a low-normal range. Other variables used for GH dose 
titration, were body weight: 62% (1319/2139), HbA1c: 
60% (1284/2139), blood pressure: 58% (1245/2139), BMI: 
58% (1240/2139), total cholesterol: 56% (1203/2139), 
high-density lipoprotein (HDL): 52% (1223/2139), 
low-density lipoprotein (LDL): 47% (1006/2139), bone 
mineral density: 41% (876/2139), waist circumference: 
34% (728/2139), and body fat: 13% (270/2139). Overall 
wellbeing and energy level was regularly asked for in 
61% of patients, while the number of sick day leave 
and partner satisfaction in less than 11%. A specific 
quality of life (QoL) questionnaire was administered for 
treatment monitoring in 45% of AGHD patients. The 
most commonly used were The QoL Assessment of GH 
Deficiency Adults questionnaire (QoL-AGHDA) and the 
Questions on Life Satisfaction Hypopituitarism Module 
(QLS-H) (21, 22). In 2%, a generic questionnaire was used 
(SF-36).
When asked whether a pituitary MRI was performed 
at initial evaluation, in 84% of the patients the answer 
was positive; in 10% this information was unavailable 
and in 6% the answer was negative; whether a CT scan 
was performed in these latter patients was not collected. 
Additionally, most centres performed new MRIs 6–12 
months after initiating GH treatment (85%) in patients 
with residual tumour, and after 12 months in patients 
without residual tumour.
In Romania, the indication of GH treatment for AGHD 
is not reimbursed. In Lithuania and Portugal, full public 
Figure 4
Number of patients diagnosed with adult growth hormone deficiency (AGHD), who were either treated or not with growth 
hormone in each centre. CO-AGHD, childhood-onset AGHD; AO-AGHD, adult-onset AGHD.
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reimbursement was approved only recently (2018–2019), 
whereas, in Slovakia, reimbursement is partial. In Greece, 
despite approval, hospital pharmacies are reluctant to 
supply GH, while in Bulgaria full public reimbursement 
is only approved in CO-AGHD. In Hungary, only those 
endocrinologists who work at accredited GH centres are 
able to prescribe GH substitution.
As far as the dispensation of the drug, it was most 
frequently dispensed in regional or reference hospital 
pharmacies (18/28), while in the others it was dispensed 
in the local pharmacy. In two countries (United Kingdom 
and Sweden) patients had the option of receiving their 
GH at home, via a registered online delivery service.
The level of satisfaction regarding available education 
and training resources and AGHD management in each 
local setting is shown in Fig. 5. While the greatest level of 
satisfaction was in the extent and quality of nurse training, 
dissatisfaction was high in relation to AGHD awareness 
by non-endocrine healthcare professionals; additionally, 
there was room for improvement in the curriculum of 
postgraduate training related to AGHD.
When the centres with a higher percentage of patients 
under GH treatment were compared to those with a lower 
percentage, a correlation was observed with a higher 
level of satisfaction in overall quality of AGHD treatment 
in the formers (P = 0.005). Not surprisingly, where full 
public treatment reimbursement was available, more GH 
treatments were prescribed (P = 0.020). Also, the level 
of satisfaction with the overall quality of AGHD patient 
treatment in each setting correlated with full public 
reimbursement of GH therapy (P = 0.018).
Discussion
We report data from a survey on current practice of AGHD 
management across Europe and benchmarked these real-
life data with pertinent guidelines (17, 18, 19, 20).
Underlying diagnoses of hypothalamic–pituitary 
disease was congruent with the guidelines. Only 81/2139 
(4%) patients with idiopathic isolated adult-onset GHD 
were reported, an entity not recognised as occurring de 
novo in adults (17).
As far as diagnostic tests, stimulation tests not 
considered valid in adults, such as GHRH alone or 
clonidine, were used in certain centres (17). Regarding the 
ITT diagnostic threshold for AGHD, most centres followed 
the European consensus of <3 µg/L (17), although 
Bratislava, Madrid and Sheffield accepted the Endocrine 
Society consensus of <5 µg/L (20). In contrast with the 
guidelines, BMI-dependent cut-off values were not always 
considered for the GHRH+arginine test (17). A low baseline 
IGF-I level was required to start GH therapy in two-thirds 
of the centres, despite that the guidelines state that a 
normal IGF-I does not rule out GHD at any age.
Administrative reasons contributed to treatment 
interruption during transition, since AGHD is not an 
approved indication for GH therapy reimbursement in 
Romania; in Lithuania and Portugal, reimbursement 
for AGHD was only recently approved. In Slovakia 
reimbursement is only partial, and in Greece hospital 
pharmacies are reluctant to supply treatment for budget 
reasons despite approval of the indication. In Bulgaria, 
full public reimbursement is only approved for adults if 
they are diagnosed as CO-AGHD. Finally, in Hungary, 
only endocrinologists who work at accredited GH centres 
are allowed to prescribe reimbursed GH substitution for 
Table 4 Causes of growth hormone treatment interruption 
in adult growth hormone deficiency patients.*
Number of patients (n = 284) % 
Adverse events 162 57
 New cancer 36 12
 Tumour recurrence 25 9





Lack of compliance 61 22
Administrative reasons 54 19
Lack of positive effect 
perceived by the patient 
51 18
Death 12 4
Not specified 106 37
*Centres were able to choose more than one cause for treatment 
interruption per patient.
Table 5 Causes of growth hormone treatment interruption 
in childhood-onset adult growth hormone deficiency during 
transition to adult care.*
Number of patients (n = 224) % 
Lack of reimbursement 75 33
Patient electing to stop the 
treatment
68 30
Discharge by the paediatric 
consultant
29 13
Poor patient compliance 15 7
Difficulty in referral to an 
adult clinic
5 2
Not known/not answered 146 64
*Centres were able to choose more than one cause for treatment 
interruption per patient.
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adults. Other reported reasons for stopping GH treatment 
at transition included patient preference, lost to follow-up 
and poor patient compliance.
Not all centres reported data on non-treated AGHD 
patients, especially in countries where most are offered 
therapy after diagnosis. In fact, the guidelines state that 
AGHD should be confirmed if treatment is a possibility. 
Thus, eligible patients in whom GH therapy was not 
initiated were not reported in many centres. Additionally, 
some patients with organic isolated AGHD could be 
underdiagnosed and therefore not reported, since up to a 
third of centres do not perform stimulation tests when the 
rest of the endocrine axes are normal; this is in line with the 
regulation in many countries, where GH treatment is not 
indicated in these cases. Even though the decision to treat 
AGHD requires a detailed evaluation of potential risks and 
benefits by knowledgeable healthcare providers, evidence is 
now convincing of the benefits of GH replacement therapy, 
especially if symptomatic and in young adults with persistent 
GHD after attaining final height, since it enables full somatic 
development, accrual of maximal bone and muscle mass, 
and improvement persists during chronic treatment (17).
Only in patients <25 years did women receive higher 
doses than men, as stated in the guidelines. After 26 
years, starting doses declined with age, but no gender 
differences in dosing were reported. In Portugal, GH dose 
was prescribed based on body weight, although this is 
not recommended in the guidelines (17). Most centres 
recommended GH to be administered in the evening, 
mimicking the greater nocturnal secretion, but this was not 
the case in over 40% of patients. Dose was initially adjusted 
after 2–3 months based on IGF-I concentration and clinical 
response, and on an annual basis thereafter; additionally, 
most centres considered adjusting the dose of other 
pituitary replacement therapies. However, it was surprising 
that only 10% considered switching oral oestrogens to a 
transdermal or transvaginal route, given the inhibitory 
effect of oral oestrogens on hepatic synthesis of IGF-I (17).
Treatment interruption due to adverse events, lack of 
compliance or perceived benefit, as well as administrative 
reasons were as expected. Twelve deaths were reported 
(0.56% of the 2139 patients), but it is not known whether 
any was related to GH therapy.
As far as safety during GH treatment, both at baseline 
and follow-up, pituitary MRIs were performed for safety 
as suggested in the guidelines; however, in long-term 
follow-up, interval between subsequent imaging depended 
on the underlying diagnosis and treatment received, that 
is, after radiotherapy, the interval between imaging was 
prolonged in some centres.
Figure 5
Level of satisfaction across centres (n = 28). AGHD, adult growth hormone deficiency.
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For efficacy, the guidelines state that IGF-I should be 
maintained within the age- and gender-related normal 
range, also if IGF-I was normal (17, 20) and this was evidenced 
in 83% of the patients in whom information was available. 
Other efficacy variables reported in approximately half the 
patients, were BMI and waist circumference, haemoglobin 
A1c, and surrogate biomarkers of cardiovascular risk 
including blood pressure and lipids.
Finally, attentive questioning to assess quality of 
life, energy level, partner satisfaction, sick day leave and 
vitality, to monitor treatment response during follow up, 
was often not contemplated, although considered essential 
(17). Overall wellbeing and energy level were routinely 
questioned in only 61%, while the number of sick days 
and partner satisfaction were recorded in less than 11%.
Good patient compliance, and to a lesser extent, 
impaired QoL and severe fatigue were considered before 
initiating GH therapy (23). In 10%, administrative issues 
(mostly lack of reimbursement) prevented GH therapy, 
whereas tumour remnants, patient age >65 years or 
diabetes mellitus prevented treatment in <5% of patients.
In the United Kingdom, impaired baseline QoL using 
the AGHDA questionnaire is a prerequisite to initiate 
GH substitution (21), and QoL is supposed to improve. 
In other countries, however, QoL questionnaires are not 
used, which is in accordance with the guidelines.
Growth hormone was predominantly provided by 
hospital pharmacies, which in some centres was enforced 
to prevent illicit use of the drug (20) or in order to reduce 
costs. Only in some countries, were central data collection 
of GH treated patients in place, allowing health authorities 
to evaluate its scope and cost.
Eighteen out of the 28 participating centres were 
satisfied with the overall quality of AGHD patients’ 
management, and especially with the extent and quality of 
nurse training. Not surprisingly, the degree of satisfaction 
was higher in centres that treated more patients than in 
those with less experience.
The global cost of orphan drugs for the 7 to 8 thousand 
rare diseases is around 5% of the global pharmaceutical 
expenditure in countries such as The Netherlands, France, 
Sweden and in Catalonia (’Report on evaluation of results: 
Treatment of rare disease with individually authorised 
drugs in the year 2019’. Barcelona. Catalan Health System. 
Department of Health. Generalitat of Catalonia; 2020. 
Accessed August 24, 2020, via: https ://ca nalsa lut.g encat 
.cat/ ca/sa lut-a -z/m/ malal ties_ minor itari es/tr actam ent). The 
contribution to this expense of substitution therapy with 
GH is minimal. Based on the results of this survey, this gap is 
an opportunity for a joint effort, of the ESE and the National 
Societies to raise awareness around AGHD, not just in the 
medical community but primarily also to health policy 
officials and funding bodies. Including this topic in the ESE 
pan-European curriculum for Endocrinology, Metabolism 
and Diabetes is also desirable (2, 3, 24, 25, 26). Improvement 
of perceived health with GH therapy, as well as long-term 
outcome and quality of life with optimal substitution 
therapy in hypopituitary patients, are strong arguments to 
offer treatment to eligible patients (27). Sharing experience 
with other patients can be very helpful (28).
Among the limitations of this survey is the variable 
participation in different countries, reaching a third of 
estimated patients in Denmark, one-fifth in Slovenia, 
and 14% in Sweden, but less than 5% of the population-
based estimation of AGHD patients in 12 countries. Some 
large countries, such as Germany, did not participate. 
Considering the gap between the estimated and captured 
AGHD patients across Europe, this disease is more 
prevalent than currently thought in practice and probably 
not so rare. Centres with less experience in the diagnosis 
and treatment of AGHD were not included, since it was 
considered of greater educational value to collect data 
from centres with at least ten treated patients.
The initial idea of comparing results from European with 
other countries was not feasible since only one Australian 
centre provided nine cases; however, it is worth mentioning 
that at survey initiation in 2017, GH was not reimbursed in 
Australia, but has now become part of the pharmaceutical 
benefit scheme. A strength, however, is collecting real-life 
data from clinical centres responsible for the diagnosis and 
management of AGHD. Given that the current guidelines 
were published in 2007 and 2016 and that since then further 
data on efficacy and safety on GH therapy in AGHD have 
become available, confirming the benefits of treatment, an 
update of the guidelines would seem pertinent.
In summary, this ESE-led audit has identified 
country-specific differences in the diagnosis and 
management of AGHD patients. Although the guidelines 
are followed to a large extent, several exceptions were 
identified. GH substitution in adults does not appear 
to be a priority among health administrators, despite 
the fact that the cost of GH treatment in comparison to 
global health costs is negligible. Despite that nearly 25 
years have passed since the initial 1996 Post Stephens 
AGHD consensus (29), equality of health care in Europe 
for rare diseases, an aim of both the European Health 
Directives and EndoERN (the European Reference 
Network for Rare Endocrine Diseases) is not globally 
guaranteed for AGHD. To improve the final outcome 
of AGHD patients; education and a greater alert of 
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the advantages of GH substitution therapy in these 
deficient patients would seem desirable, including by 
non-endocrine healthcare providers.
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